Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saul Genuth

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
The American Journal of Cardiology|July 4, 2006
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) TrialMaria Mori Brooks, Robert L Frye, Saul Genuth, et al.
Journal of Diabetes and Its Complications|March 13, 2013
Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysisFaramarz Ismail-Beigi, Manuel S Lombardero, Jorge Escobedo, et al.
The American Journal of Cardiology|July 12, 2007
Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE)Emily Y Chew, Walter T Ambrosius, Letitia T Howard, et al.
Diabetes Care|March 11, 2010
Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialRodica Pop-Busui, Gregory W Evans, Hertzel C Gerstein, et al.
Diabetes|November 30, 2006
The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) StudyPatricia A Cleary, Trevor J Orchard, Saul Genuth, et al.
Circulation|July 17, 2013
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trialRichard G Bach, Maria Mori Brooks, Manuel Lombardero, et al.
Circulation|July 20, 2011
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trialBurton E Sobel, Regina M Hardison, Saul Genuth, et al.
Circulation|April 23, 2014
Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial"Richard G Bach, Maria Mori Brooks, Manuel Lombardero, et al.
The American Journal of Cardiology|July 12, 2007
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialDavid C Goff, Hertzel C Gerstein, Henry N Ginsberg, et al.
Kidney International|December 15, 2011
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patientsFaramarz Ismail-Beigi, Timothy E Craven, Patrick J O'Connor, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
The American Journal of Cardiology|July 4, 2006
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) TrialMaria Mori Brooks, Robert L Frye, Saul Genuth, et al.
Journal of Diabetes and Its Complications|March 13, 2013
Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysisFaramarz Ismail-Beigi, Manuel S Lombardero, Jorge Escobedo, et al.
The American Journal of Cardiology|July 12, 2007
Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE)Emily Y Chew, Walter T Ambrosius, Letitia T Howard, et al.
Diabetes Care|March 11, 2010
Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialRodica Pop-Busui, Gregory W Evans, Hertzel C Gerstein, et al.
Diabetes|November 30, 2006
The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) StudyPatricia A Cleary, Trevor J Orchard, Saul Genuth, et al.
Circulation|July 17, 2013
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trialRichard G Bach, Maria Mori Brooks, Manuel Lombardero, et al.
Circulation|July 20, 2011
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trialBurton E Sobel, Regina M Hardison, Saul Genuth, et al.
Circulation|April 23, 2014
Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial"Richard G Bach, Maria Mori Brooks, Manuel Lombardero, et al.
The American Journal of Cardiology|July 12, 2007
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialDavid C Goff, Hertzel C Gerstein, Henry N Ginsberg, et al.
Kidney International|December 15, 2011
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patientsFaramarz Ismail-Beigi, Timothy E Craven, Patrick J O'Connor, et al.
Pageof 6